Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis. It is also developing SEL-403 product candidate, a combination therapy comprising SVP-rapamycin and LMB-100, which is in Phase I clinical trial for the treatment of patients with malignant pleural or peritoneal mesothelioma; and SELA-070, a nicotine vaccine product candidate that is in Phase I clinical trial for smoking cessation and relapse prevention. In addition, the company engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a lead gene therapy program for the treatment methylmalonic academia; and SEL-313, a gene therapy product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., BIND Therapeutics, Inc., and Massachusetts Eye and Ear Infirmary, as well as research collaboration agreements with National Cancer Institute. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SELB
Previous Symbol
CUSIPN/A
Phone617-923-1400
Debt
Debt-to-Equity RatioN/A
Current Ratio1.60
Quick Ratio1.60
Price-To-Earnings
Trailing P/E Ratio-1.72
Forward P/E Ratio-1.79
P/E GrowthN/A
Sales & Book Value
Annual Sales$210,000.00
Price / Sales586.38
Cash FlowN/A
Price / CashN/A
Book Value$2.32 per share
Price / Book2.37
Profitability
EPS (Most Recent Fiscal Year)($3.20)
Net Income$-65,320,000.00
Net MarginsN/A
Return on Equity-220.07%
Return on Assets-86.49%
Miscellaneous
Employees64
Outstanding Shares22,430,000
Market Cap$123.61 million
OptionableOptionable
Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions
What is Selecta Biosciences' stock symbol?
Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."
How were Selecta Biosciences' earnings last quarter?
Selecta Biosciences Inc (NASDAQ:SELB) issued its quarterly earnings results on Thursday, November, 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.79) by $0.08. View Selecta Biosciences' Earnings History.
When is Selecta Biosciences' next earnings date?
What price target have analysts set for SELB?
5 analysts have issued 1-year price targets for Selecta Biosciences' shares. Their predictions range from $6.00 to $40.00. On average, they expect Selecta Biosciences' stock price to reach $26.60 in the next twelve months. This suggests a possible upside of 384.5% from the stock's current price. View Analyst Price Targets for Selecta Biosciences.
What is the consensus analysts' recommendation for Selecta Biosciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Selecta Biosciences.
What are Wall Street analysts saying about Selecta Biosciences stock?
Here are some recent quotes from research analysts about Selecta Biosciences stock:
- 1. Mizuho analysts commented, "We hosted a doc call on 10/29 to discuss SEL-212. Our consultant noted some of the main potential advantages of SEL-212 vs. the standard of care including; 1) Improved treatment regimen with fewer infusions (1x/month) vs. a proposed Krystexxa combo (2x/month + daily or weekly anti-proliferative agent) and 2) Superior safety profile. Our consultant believes SEL-212 is ready for phase 3 given considerable amounts of data generated to date on treatment regimen and dosing along with clear objective measurements showing tophi mitigation and lowering of uric acid levels in a majority of patients. She argued that had the stopping rules not been as stringent in the phase 2 trial, the results may have looked better." (11/5/2018)
- 2. According to Zacks Investment Research, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. " (10/10/2018)
- 3. Canaccord Genuity analysts commented, "We expect Selecta to present positive 5-dose Phase 2 combination data for SEL-212 in severe gout during 3Q18, and see significant upside for the stock. Selecta is likely to present data from multiple dosing cohorts, with up to n=20 patients from each cohort. We suspect focus will be on the 0.15 mg/kg SVP-rapamycin + 0.20 pegsiticase dose, but await upcoming data. We see little reason that SEL-212 will not reproduce data at 5 months similar to that seen at 3 months, where ~80% Serum Uric Acid control was shown." (7/11/2018)
Has Selecta Biosciences been receiving favorable news coverage?
Headlines about SELB stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Selecta Biosciences earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an impact on the stock's share price in the near future.
Who are some of Selecta Biosciences' key competitors?
Some companies that are related to Selecta Biosciences include Xeris Pharmaceuticals (XERS), Aurinia Pharmaceuticals (AUPH), Dova Pharmaceuticals (DOVA), Rigel Pharmaceuticals (RIGL), Kezar Life Sciences (KZR), Eidos Therapeutics (EIDX), Odonate Therapeutics (ODT), TG Therapeutics (TGTX), Theratechnologies (THERF), Progenics Pharmaceuticals (PGNX), Corium International (CORI), Clementia Pharmaceuticals (CMTA), Kura Oncology (KURA), Kindred Biosciences (KIN) and Beyondspring (BYSI).
Who are Selecta Biosciences' key executives?
Selecta Biosciences' management team includes the folowing people:
- Dr. Omid C. Farokhzad, Co-Founder, Chairman & Member of the Scientific Advisory Board (Age 49)
- Dr. Werner Cautreels, Pres, CEO & Director (Age 66)
- Dr. John H. Leaman, CFO, Head of Corp. Strategy & Treasurer (Age 45)
- Dr. Lloyd Johnston, COO and Sr. VP of R&D (Age 50)
- Dr. Ulrich H. von Andrian-Werburg, Co-Founder and Co-Chair of the Scientific Advisory Board
When did Selecta Biosciences IPO?
(SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.
Who are Selecta Biosciences' major shareholders?
Selecta Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.01%), JPMorgan Chase & Co. (2.78%), Artal Group S.A. (2.51%) and Virtu Financial LLC (0.10%). Company insiders that own Selecta Biosciences stock include Amir Nashat, David Abraham, David Siewers, Earl Sands, Edwin M Kania, Jr, Lloyd P Johnston, Peter Keller, Takashi Kei Kishimoto, Timothy A Springer, Timothy C Barabe and Werner Cautreels. View Institutional Ownership Trends for Selecta Biosciences.
Which institutional investors are selling Selecta Biosciences stock?
Which institutional investors are buying Selecta Biosciences stock?
SELB stock was bought by a variety of institutional investors in the last quarter, including Artal Group S.A., Virtu Financial LLC and BlackRock Inc.. Company insiders that have bought Selecta Biosciences stock in the last two years include Earl Sands, Timothy A Springer, Timothy C Barabe and Werner Cautreels. View Insider Buying and Selling for Selecta Biosciences.
How do I buy shares of Selecta Biosciences?
Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Selecta Biosciences' stock price today?
One share of SELB stock can currently be purchased for approximately $5.49.
How big of a company is Selecta Biosciences?
Selecta Biosciences has a market capitalization of $123.61 million and generates $210,000.00 in revenue each year. The company earns $-65,320,000.00 in net income (profit) each year or ($3.20) on an earnings per share basis. Selecta Biosciences employs 64 workers across the globe.
What is Selecta Biosciences' official website?
How can I contact Selecta Biosciences?
Selecta Biosciences' mailing address is 480 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected]
MarketBeat Community Rating for Selecta Biosciences (NASDAQ SELB)
MarketBeat's community ratings are surveys of what our community members think about Selecta Biosciences and other stocks. Vote "Outperform" if you believe SELB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SELB will underperform the S&P 500 over the long term. You may vote once every thirty days.
